Plans will pay 3.5% of premiums in federal exchanges
New guidelines from HHS reveal a fee equal to 3.5% of premiums for plans participating in federal exchanges.
When the Department of Health and Human Services (HHS) produced new guidance for health plans participating in insurance exchanges, there’s no doubt plan executives started doing a little math in their heads.
Any plan that qualifies and sells its products in the federally operated exchanges will pay a participation fee of 3.5% of premiums, according to the HHS filing. The actual dollar amount is nearly impossible to estimate right now because there are still so many variables to play out over the next several months.
Many of the up-and-coming features of healthcare reform force fees, taxes and costly administrative burdens on insurers. However, the assumption is that plans will benefit from new business so they must pay to participate in the fed’s readymade marketplace.
Private insurance exchanges and health information exchanges-the data hubs that have been inching along in recent years-also charge fees to participants. It’s the typical funding model.
And it works both ways.
In Minnesota, for example, the current state-subsidized plan for low-income families that don’t qualify for Medicaid is funded in part by a 2% tax paid by providers. It covers 148,000 individuals, and only those who are of low or moderate income and have been uninsured for at least four months qualify.
Go back to the Managed Healthcare Executive eNews newsletter.
Premiums for Employer-based Health Insurance Increased by 7% in 2024, Says KFF Report
Published: October 9th 2024 | Updated: October 9th 2024The 2024 increase is the same as last year's increase for family coverage. The foundation’s annual survey of employer health benefits also found that only 18% of large employers (200 employees are more) are covering the GLP-1 weight loss drugs.
Read More
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Doug Chaet of Value Evolutions Discusses Value-based Payment Models, Where They Stand and More
September 29th 2022In this episode of Tuning In to the C-Suite, Managing Editor of Managed Healthcare Executive, Peter Wehrwein, speaks with President of Value Evolutions and MHE Editorial Advisory Board Member, Doug Chaet, FACHE, about value-based care's current standing, the status of select payment models like bundled and episodic, and more.
Listen
Parity for Mental Health — Any Progress?
October 12th 2023Laws since 1996 have sought to assure that coverage of behavioral health treatments does not take a back seat to physical medicine. Amid a national crisis in mental illness and addiction, that new world of equality has not arrived. But is it on the way?
Read More
